Saturday, March 25, 2017
Breaking News


5mg d-amphetamine sulfate tablets

5mg d-amphetamine sulfate tablets

Dextroamphetamine is Schedule II in the United States. This means it is illegal to sell without a DEA license and illegal to buy or possess without a license or prescription.

Addictive Potential: High

Emergency Room Visits Yearly: Unknown

Mandatory Minimum Sentence: Not more than 20 years in prison

Mechanism of Action: Increases the Neurotransmitters Dopamine and Norepinephrine


Dextroamphetamine is a psychostimulant drug which is known to produce increased wakefulness and focus in association with decreased fatigue and decreased appetite. Dextroamphetamine is the dextrorotary or “Right-handed” stereoisomer of the amphetamine molecule. The amphetamine molecule has 2 stereoisomers: levo-amphetamine “left-handed” and dextro-amphetamine “right-handed”. Names for dextroamphetamine include d-amphetamine, dexamphetamine, and (S)-(+)-amphetamine, and brand names for dextroamphetamine include Dexedrine and Dextrostat. It is the active metabolite of the ‘prodrug’ lisdexamfetamine, known by its brand name Vyvanse and makes up approximately 72% of ADHD drug Adderall. In addition, dextroamphetamine is an active metabolite of several older N-substituted amphetamine prodrugs used as anorectics, such as clobenzorex (Asenlix), benzphetamine (Didrex), and amphetaminil (Aponeuron).


Withdrawal symptoms of dextroamphetamine primarily consist of fatigue, depression and an increased appetite. Symptoms may last for days with occasional use and weeks or months with chronic use, with severity dependent on the length of time and the amount of dextroamphetamine used. Withdrawal symptoms may also include anxiety, irritability, headaches, agitation, seizures, vomiting, akathisia, hypersomnia (excessive sleeping), vivid or lucid dreams, deep REM sleep and suicidal ideation.


Potential Adverse Effects of Amphetamine Treatment on Brain and Behavior: A Review

More Info:

Full List of Childrens’ Psychiatric Medications

Leave a Reply